

## Special Issue

# The Latest Advancements in Tumor Drug Delivery Systems

### Message from the Guest Editor

With the rising incidence of tumors and the increasing demand for treatment, "Tumor Drug Delivery System" stands as a critical direction to address the limitations of conventional chemotherapy. This Special Issue will focus on the latest research advancements, technological innovations, and clinical applications of tumor drug delivery systems, offering a comprehensive and in-depth academic platform for readers.

*Biomedicines* has launched a Special Issue dedicated to providing an in-depth overview of the latest advancements in tumor drug delivery systems, which encompasses but is not limited to:

- Design and Synthesis of Multi-functional Nanocarriers (e.g., lipid nanoparticles, viral vectors, and magnetic nanoparticles)
- Development of intelligent drug delivery systems (e.g., photo-responsive systems, temperature-responsive systems, or near-infrared light-activated systems)
- Biomedical applications of biomimetic delivery systems for tumor targeting efficiency
- Research and development of tumor vaccines
- AI-driven optimization strategies for drug delivery systems

### Guest Editor

Dr. Mingji Jin

State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Department of Pharmaceuticals, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China

### Deadline for manuscript submissions

31 January 2026



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/244997](https://mdpi.com/si/244997)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).